MCID: THR004
MIFTS: 52

Thrombocytosis

Categories: Blood diseases

Aliases & Classifications for Thrombocytosis

MalaCards integrated aliases for Thrombocytosis:

Name: Thrombocytosis 12 75 29 55 44 15 72
Thrombocythaemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2228
MeSH 44 D013922
NCIt 50 C35530
SNOMED-CT 68 6631009 79574003
UMLS 72 C0836924

Summaries for Thrombocytosis

Disease Ontology : 12 A blood platelet disease that is characterized by the presence of high platelet counts in the blood.

MalaCards based summary : Thrombocytosis, also known as thrombocythaemia, is related to thrombocythemia 1 and myeloproliferative neoplasm. An important gene associated with Thrombocytosis is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are hematopoietic system and cardiovascular system

Wikipedia : 75 Thrombocythemia is the presence of high platelet (thrombocyte) counts in the blood, and can be either... more...

Related Diseases for Thrombocytosis

Diseases related to Thrombocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 629)
# Related Disease Score Top Affiliating Genes
1 thrombocythemia 1 34.1 THPO MPL
2 myeloproliferative neoplasm 31.6 TET2 MPL JAK2
3 polycythemia vera 31.6 THPO TET2 SELP MPL JAK2 IL3
4 splenomegaly 31.4 MPL JAK2 EPO
5 chromosome 5q deletion syndrome 31.1 TET2 EPO
6 iron deficiency anemia 30.9 THPO IL6 EPO CRP
7 refractory anemia 30.7 TET2 MPL JAK2 IL3 EPO
8 polycythemia 30.5 THPO TET2 MPL JAK2 IL3 EPO
9 myeloid leukemia 30.5 TET2 JAK2 IL3 CSF2
10 amegakaryocytic thrombocytopenia, congenital 30.4 THPO MPL IL3
11 myelofibrosis 30.4 THPO TET2 MPL JAK2 IL3 EPO
12 portal hypertension 30.4 THPO JAK2 F2
13 thrombocytopenia 30.4 THPO MPL IL11 F3
14 pneumonia 30.3 IL6 IL1B CRP
15 poems syndrome 30.2 IL6 IL1B EPO
16 deficiency anemia 30.2 THPO IL6 IL3 IL11 EPO CRP
17 bacterial meningitis 30.2 IL6 IL1B CRP
18 meningitis 30.2 IL6 IL1B CRP
19 thrombocytopenia due to platelet alloimmunization 30.2 THPO SELP MPL
20 gastroenteritis 30.2 IL6 IL1B CRP
21 essential thrombocythemia 30.1 THPO TET2 SELP MPL JAK2 IL3
22 end stage renal failure 30.1 IL6 EPO CRP
23 juvenile rheumatoid arthritis 30.1 IL6 IL1B CRP
24 erythrocytosis, familial, 1 30.1 THPO JAK2 IL3 EPO
25 platelet aggregation, spontaneous 30.0 SERPINC1 SELP
26 thrombocytopenic purpura, autoimmune 30.0 THPO SELP MPL IL11
27 blood platelet disease 30.0 THPO SERPINC1 SELP MPL JAK2 F3
28 ulcerative colitis 29.9 IL6 IL1B CRP
29 acute monoblastic leukemia 29.8 IL6 EPO CSF2
30 neutrophilia, hereditary 29.8 JAK2 IL6 CSF2 CRP
31 leukemia, chronic myeloid 29.8 THPO MPL JAK2 IL3 EPO CSF2
32 chronic myelomonocytic leukemia 29.8 TET2 JAK2 CSF2
33 angina pectoris 29.8 SERPINC1 IL6 CRP
34 leukemia, acute myeloid 29.8 THPO TET2 MPL JAK2 IL3 CSF2
35 psoriatic arthritis 29.7 IL6 IL1B CRP
36 anemia of prematurity 29.7 IL3 EPO CSF2
37 spinal cord infarction 29.7 SERPINC1 F2
38 central retinal vein occlusion 29.7 SERPINC1 IL6 F2
39 retinal vein occlusion 29.7 SERPINC1 IL6 F2
40 coronary heart disease 1 29.6 SELP IL6 CRP
41 cerebral palsy 29.6 IL6 IL1B F2
42 sarcoidosis 1 29.6 IL3 IL1B CSF2
43 bacterial infectious disease 29.6 IL6 IL1B CSF2 CRP
44 thrombophilia due to thrombin defect 29.6 SERPINC1 F3 F2
45 portal vein thrombosis 29.6 SERPINC1 SELP JAK2 F2
46 intracranial embolism 29.6 SERPINC1 F2
47 perinatal necrotizing enterocolitis 29.5 THPO IL6 IL1B CRP
48 pancytopenia 29.5 THPO MPL IL3 EPO CSF2
49 megakaryocytic leukemia 29.5 THPO JAK2 IL3 IL11 CSF2
50 myeloma, multiple 29.5 JAK2 IL6 EPO CSF2 CRP

Graphical network of the top 20 diseases related to Thrombocytosis:



Diseases related to Thrombocytosis

Symptoms & Phenotypes for Thrombocytosis

MGI Mouse Phenotypes related to Thrombocytosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 CSF2 EPO F2 F3 IL1B IL6
2 cardiovascular system MP:0005385 10.16 CRP CSF2 EPO F2 F3 IL1B
3 homeostasis/metabolism MP:0005376 10.15 CRP CSF2 EPO F2 F3 IL1B
4 immune system MP:0005387 10.13 CRP CSF2 EPO F2 F3 IL1B
5 embryo MP:0005380 9.98 CSF2 EPO F2 F3 JAK2 MPL
6 integument MP:0010771 9.86 CSF2 EPO F2 F3 IL1B IL6
7 mortality/aging MP:0010768 9.7 CSF2 EPO F2 F3 IL1B IL6
8 liver/biliary system MP:0005370 9.63 EPO IL6 JAK2 SELP SERPINC1 TET2
9 neoplasm MP:0002006 9.1 CSF2 F3 IL1B IL6 JAK2 TET2

Drugs & Therapeutics for Thrombocytosis

Drugs for Thrombocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
3
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
4
Anagrelide Approved Phase 3 68475-42-3 2182
5
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
6
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
7
Hydroxyurea Approved Phase 3 127-07-1 3657
8
Mercaptopurine Approved Phase 3 50-44-2 667490
9
Danazol Approved Phase 3 17230-88-5 28417
10
Melphalan Approved Phase 3 148-82-3 460612 4053
11
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
12
Lactitol Investigational Phase 2, Phase 3 585-86-4, 585-88-6 493591
13 Antirheumatic Agents Phase 3
14 Analgesics Phase 3
15 Anti-Inflammatory Agents Phase 3
16 Analgesics, Non-Narcotic Phase 3
17 Anti-Inflammatory Agents, Non-Steroidal Phase 3
18 Peripheral Nervous System Agents Phase 3
19 Cyclooxygenase Inhibitors Phase 3
20 Antipyretics Phase 3
21 Fibrinolytic Agents Phase 2, Phase 3
22 Platelet Aggregation Inhibitors Phase 2, Phase 3
23 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
24 Interferon-alpha Phase 2, Phase 3
25 Protein Kinase Inhibitors Phase 3
26 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3
27 Immunologic Factors Phase 3
28 Anti-Infective Agents Phase 3
29 Antiviral Agents Phase 3
30 Androgens Phase 3
31 Mitogens Phase 3
32 Interferon alpha-2 Phase 3
33 interferons Phase 3
34 Janus Kinase Inhibitors Phase 3
35 glucocorticoids Phase 3
36
Panobinostat Approved, Investigational Phase 1, Phase 2 404950-80-7 6918837
37
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
38
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
39
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
40
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
41
Pomalidomide Approved Phase 2 19171-19-8
42
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
43
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
44
Lenalidomide Approved Phase 2 191732-72-6 216326
45
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
46
leucovorin Approved Phase 2 58-05-9 143 6006
47
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
48
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
49
Mirabegron Approved Phase 2 223673-61-8 9865528
50
Ticagrelor Approved Phase 2 274693-27-5 9871419

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
2 A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients. Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
3 A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial Completed NCT00774566 Phase 4
4 An Open Label, Multi-center, Phase IV Roll-over Protocol for Patients Who Have Completed a Prior Global Novartis or Incyte Sponsored Ruxolitinib (INC424) Study and Are Judged by the Investigator to Benefit From Continued Treatment Recruiting NCT02386800 Phase 4 Ruxolitinib
5 A Multicenter, Open-label, Clinical Study for Efficacy and Safety Evaluation of Anagrelide in Patients With Treatment-naïve, High-risk Essential Thrombocythemia as a Primary Treatment Recruiting NCT03232177 Phase 4 Anagre Cap.
6 A Single Blind, Multi-centre, Randomised Multinational Phase III Study to Compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients With Essential Thrombocythaemia Completed NCT01065038 Phase 3 Anagrelide;Hydroxyurea
7 A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Completed NCT01467661 Phase 3 SPD422 (anagrelide hydrochloride)
8 A Phase 3, Open-label, Single-arm Study Evaluating the Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Who Are Intolerant or Refractory to Current Cytoreductive Treatment Completed NCT01214915 Phase 3 Anagrelide Hydrochloride
9 A Phase III, Randomized, Multicenter, Subject and Sponsor-blinded, Placebo Controlled Study to Compare the Efficacy and Safety of "Anagrelide Retard" Versus Placebo in "at Risk" Subjects With Essential Thrombocythaemia Completed NCT01230775 Phase 3 Anagrelide retard;Placebo
10 A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
11 An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF). Completed NCT01493414 Phase 3 INC424
12 A Phase III Randomized, Multicenter, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythemia (TEAM-ET 2.0) Completed NCT02076815 Phase 3 Anagrelide retard;Thromboreductin
13 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
14 A Phase 3b, Multicenter, Single-arm, Open-label Safety AND Efficacy Study of Fedratinib in Subjects With DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Recruiting NCT03755518 Phase 3 FEDRATINIB
15 French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study Recruiting NCT02611973 Phase 3 Hydroxyurea treatment (HU)
16 A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
17 A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study Active, not recruiting NCT02962388 Phase 2, Phase 3 Anagrelide;Ruxolitinib (JAKAVI®);IFNα/ PegIFNα
18 A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
19 Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms. Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
20 A MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FEDRATINIB COMPARED TO BEST AVAILABLE THERAPY IN SUBJECTS WITH DIPSS-INTERMEDIATE OR HIGH-RISK PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS AND PREVIOUSLY TREATED WITH RUXOLITINIB Not yet recruiting NCT03952039 Phase 3 FEDRATINIB;Best Available Therapy (BAT)
21 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
22 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
23 A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia. Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
24 A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients With Primary Myelofibrosis (PMF) and Post-polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Unknown status NCT01298934 Phase 1, Phase 2 LBH589
25 A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults With Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
26 A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamic and Safety Study of Anagrelide Hydrochloride in Young (18-50 Years) and Elderly (≥ 65 Years) Patients With Essential Thrombocythaemia. Completed NCT00413634 Phase 2 anagrelide hydrochloride
27 An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation Completed NCT00586651 Phase 2 lestaurtinib
28 A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Completed NCT02515630 Phase 2 MMB
29 A Phase 2, Open Label Efficacy and Safety Study of Anagrelide Controlled Release (CR) in Subjects With Thrombocytosis Secondary to Essential Thrombocythemia and Other Myeloproliferative Neoplasms (MPN) Completed NCT02125318 Phase 2 Anagrelide CR
30 A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy Completed NCT01243073 Phase 2 Imetelstat
31 A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis Completed NCT01392443 Phase 2 Ruxolitinib
32 A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis Completed NCT00745550 Phase 1, Phase 2 SB1518
33 Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia Completed NCT02124746 Phase 2 Momelotinib
34 An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L Completed NCT01348490 Phase 2 Ruxolitinib (INCB018424)
35 A Multicenter Phase II, Open Label, Single Arm Study to Evaluate the Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. Completed NCT02966353 Phase 2 ruxolitinib
36 A Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known as STI-571) In Patients With Myelofibrosis Completed NCT00039416 Phase 2 imatinib mesylate
37 A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Subjects With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis Completed NCT01369498 Phase 2 Simtuzumab;Ruxolitinib
38 A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET) Completed NCT00509899 Phase 1, Phase 2 Ruxolitinib
39 Multi-Center Phase II Study With Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Completed NCT00949364 Phase 2 Pomalidomide
40 A Phase 2, Open Label, Dose Regimen Ranging Clinical Study to Determine the Safety and Efficacy of INCB018424 in Patients With Advanced Polycythemia Vera or Essential Thrombocythemia Refractory to Hydroxyurea Completed NCT00726232 Phase 2 Ruxolitinib
41 A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01692366 Phase 2 SAR302503
42 A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia Completed NCT00227591 Phase 2 lenalidomide;prednisone
43 A Phase II Trial of R115777 in Myelofibrosis With Myeloid Metaplasia (MMM) Completed NCT00047190 Phase 2 tipifarnib
44 Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT) Completed NCT00003239 Phase 2 Cytarabine;Omacetaxine Mepesuccinate
45 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
46 A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies Completed NCT01731951 Phase 2 Imetelstat
47 A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis Completed NCT01787552 Phase 1, Phase 2 LDE225;INC424
48 Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC) Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
49 A Phase II, Open-Label Extension Study Evaluating the Long Term Safety, Tolerability & Efficacy of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01236638 Phase 2 Momelotinib
50 A Phase I/II, Open-Label Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01423058 Phase 1, Phase 2 Momelotinib

Search NIH Clinical Center for Thrombocytosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Anagrelide
Chlorambucil
Uracil Mustard

Cochrane evidence based reviews: thrombocytosis

Genetic Tests for Thrombocytosis

Genetic tests related to Thrombocytosis:

# Genetic test Affiliating Genes
1 Thrombocytosis 29

Anatomical Context for Thrombocytosis

MalaCards organs/tissues related to Thrombocytosis:

41
Myeloid, Bone, Bone Marrow, Lung, Liver, Testes, Neutrophil

Publications for Thrombocytosis

Articles related to Thrombocytosis:

(show top 50) (show all 4894)
# Title Authors PMID Year
1
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. 9 38
20154217 2010
2
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. 9 38
20151976 2010
3
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. 9 38
20197548 2010
4
Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. 9 38
19903679 2010
5
JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. 9 38
19643476 2010
6
Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. 9 38
20194236 2010
7
Class prediction models of thrombocytosis using genetic biomarkers. 9 38
19773543 2010
8
[Diabetes insipidus followed, after 4 years, with dysarthria and mild right-sided hemiparesis--the first clinical signs of Erdheim-Chester disease. Description and depiction of a case with a review of information on the disease]. 9 38
20070034 2009
9
[Paediatric myofibroblastic tumours. A presentation of three cases]. 9 38
19647502 2009
10
JAK2 V617F mutation and PRV-1 overexpression: relevance in the diagnosis of polycythaemia vera and essential thrombocythaemia. 9 38
19999391 2009
11
Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. 9 38
19657484 2009
12
Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency. 9 38
19303685 2009
13
Granulocytosis and thrombocytosis in renal cell carcinoma: a pro-inflammatory cytokine response originating in the tumour. 9 38
19581670 2009
14
Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia. 9 38
19252138 2009
15
A case of acute promyelocytic leukemia showing transient thrombocytosis caused by increased interleukin-6 and thrombopoietin after treatment with all-trans retinoic acid and chemotherapy. 9 38
19461187 2009
16
The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia. 9 38
19222478 2009
17
[A case of IL-6 producing malignant mesothelioma of abdomen with thrombocytosis]. 9 38
19346724 2009
18
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. 9 38
18845793 2009
19
Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. 9 38
18796624 2009
20
Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. 9 38
19036112 2009
21
Mice overexpressing murine oncostatin M (OSM) exhibit changes in hematopoietic and other organs that are distinct from those of mice overexpressing human OSM or bovine OSM. 9 38
19112126 2009
22
Anagrelide: 20 years later. 9 38
19105705 2009
23
Thrombocytosis. 9 38
20008195 2009
24
General changes in hemostasis in gastric cancer. 9 38
19507648 2009
25
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation. 9 38
19174256 2009
26
Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. 9 38
18760517 2008
27
Familial chronic myeloproliferative disorders: the state of the art. 9 38
18484677 2008
28
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. 9 38
18367486 2008
29
Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role? 9 38
18397204 2008
30
Incidence and clinical significance of left ventricular thrombus in tako-tsubo cardiomyopathy assessed with echocardiography. 9 38
18334499 2008
31
High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. 9 38
18616871 2008
32
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. 9 38
18160670 2008
33
Clinical implications of JAK2 mutations in myeloproliferative disorders. 9 38
18575049 2008
34
Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. 9 38
17688946 2008
35
Thrombopoietin levels increased in patients with severe acute respiratory syndrome. 9 38
18314161 2008
36
Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. 9 38
18041648 2007
37
JAK2 mutations and clinical practice in myeloproliferative neoplasms. 9 38
18032973 2007
38
Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. 9 38
17920755 2007
39
Neonatal thrombocytosis following G-CSF treatment. 9 38
17917868 2007
40
Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle? 9 38
18220909 2007
41
Essential versus reactive thrombocythemia in children: retrospective analyses of 12 cases. 9 38
17171694 2007
42
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation. 9 38
17285276 2007
43
[JAK2(V617F) mutation in Korean patients with essential thrombocythemia]. 9 38
18094555 2007
44
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. 9 38
16820206 2007
45
[Blood cytokine levels as a clinical laboratory test]. 9 38
17441472 2007
46
JAK-2 mutations and their relevance to myeloproliferative disease. 9 38
17133099 2007
47
Characteristic changes in platelet-large cell ratio, lactate dehydrogenase and C-reactive protein in thrombocytosis-related diseases. 9 38
17622783 2007
48
Thrombopoietin and interleukin-6 levels in Henoch-Schönlein purpura. 9 38
17164950 2006
49
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. 9 38
16912229 2006
50
Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders. 9 38
17249502 2006

Variations for Thrombocytosis

Expression for Thrombocytosis

Search GEO for disease gene expression data for Thrombocytosis.

Pathways for Thrombocytosis

Pathways related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 THPO MPL JAK2 IL6 IL3 IL1B
2
Show member pathways
13.39 THPO MPL JAK2 IL6 IL3 IL1B
3
Show member pathways
13.31 THPO JAK2 IL6 IL3 IL1B IL11
4
Show member pathways
13.28 JAK2 IL6 IL3 IL1B IL11 CSF2
5
Show member pathways
13.2 THPO JAK2 IL6 IL3 IL1B IL11
6
Show member pathways
13.1 THPO SERPINC1 SELP MPL JAK2 IL3
7
Show member pathways
12.98 THPO JAK2 IL6 IL3 F2
8
Show member pathways
12.52 JAK2 IL6 IL1B F2
9 12.49 MPL JAK2 IL3 IL1B
10
Show member pathways
12.27 IL6 IL1B F2 CRP
11
Show member pathways
12.26 JAK2 IL6 IL1B CSF2
12
Show member pathways
12.2 THPO IL6 IL3 IL1B
13
Show member pathways
12.12 JAK2 IL6 IL1B IL11
14
Show member pathways
12.12 THPO MPL JAK2 IL6 IL3 IL11
15 12.02 SERPINC1 F3 F2
16 12.01 THPO IL6 IL3 IL11
17
Show member pathways
11.99 JAK2 IL6 IL1B
18
Show member pathways
11.98 IL6 IL1B F2 CSF2
19 11.95 SELP IL6 IL1B
20 11.92 JAK2 IL6 IL1B
21
Show member pathways
11.92 THPO JAK2 IL6 IL3 IL1B IL11
22 11.9 IL6 IL1B CSF2
23 11.87 IL6 IL3 IL1B
24 11.85 IL6 IL1B CSF2
25
Show member pathways
11.84 THPO MPL F2
26 11.83 THPO MPL JAK2 CRP
27 11.83 JAK2 IL6 IL1B F3
28
Show member pathways
11.81 JAK2 IL6 CSF2
29 11.81 JAK2 IL6 IL3 EPO
30 11.78 IL6 IL1B IL11 CSF2
31
Show member pathways
11.77 JAK2 IL6 CRP
32 11.75 IL6 IL1B CSF2
33 11.7 IL6 IL1B CSF2
34 11.67 IL6 IL1B CSF2
35
Show member pathways
11.62 IL6 IL1B CSF2
36 11.61 IL6 IL1B CSF2
37
Show member pathways
11.56 JAK2 IL6 IL11
38 11.56 THPO MPL IL6 IL3 IL11 EPO
39 11.48 SELP IL6 IL1B
40 11.47 IL6 IL1B CSF2
41 11.4 IL6 IL3 IL1B EPO CSF2
42 11.39 IL6 IL3 IL11 EPO
43 11.21 THPO MPL JAK2 CRP
44 11.15 THPO IL6 IL3 IL1B IL11 EPO
45 11.12 IL6 IL3 IL1B IL11 CSF2
46 11.11 IL6 IL3 IL1B IL11 CSF2
47 10.98 IL6 CRP
48 10.92 THPO IL6 IL3 IL1B IL11 CSF2

GO Terms for Thrombocytosis

Cellular components related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 THPO SERPINC1 IL6 IL3 IL1B IL11
2 extracellular space GO:0005615 9.4 THPO SERPINC1 SELP IL6 IL3 IL1B

Biological processes related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.88 SELP IL6 IL1B CRP
2 MAPK cascade GO:0000165 9.8 JAK2 IL3 IL1B CSF2
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.74 JAK2 IL6 IL1B
4 blood coagulation GO:0007596 9.73 SERPINC1 JAK2 F3 F2
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 SELP JAK2 F2
6 response to lipopolysaccharide GO:0032496 9.67 SELP JAK2 IL1B EPO
7 hemostasis GO:0007599 9.63 SERPINC1 F3 F2
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.62 JAK2 IL6 IL3 IL11
9 positive regulation of cell proliferation GO:0008284 9.61 THPO JAK2 IL6 IL3 IL1B IL11
10 positive regulation of glial cell proliferation GO:0060252 9.58 IL6 IL1B
11 interleukin-6-mediated signaling pathway GO:0070102 9.56 JAK2 IL6
12 acute-phase response GO:0006953 9.56 IL6 F2 EPO CRP
13 regulation of blood coagulation GO:0030193 9.55 SERPINC1 F2
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.55 JAK2 IL6 IL3 EPO CSF2
15 negative regulation of lipid storage GO:0010888 9.52 IL6 CRP
16 positive regulation of neuroinflammatory response GO:0150078 9.48 IL6 IL1B
17 thrombopoietin-mediated signaling pathway GO:0038163 9.4 THPO MPL
18 response to dexamethasone GO:0071548 9.24 EPO
19 cytokine-mediated signaling pathway GO:0019221 9.23 MPL JAK2 IL6 IL3 IL1B IL11

Molecular functions related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 THPO IL6 IL3 IL11 F2 CSF2
2 cytokine activity GO:0005125 9.17 THPO IL6 IL3 IL1B IL11 EPO

Sources for Thrombocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....